Drug Trial Radar · NCT06952660
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 7, 2025
Primary completion
Dec 13, 2028
Study completion Dec 13, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Genmab
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.
Conditions
- Cervical Cancer
Interventions
TIVDAKDrug
2 mg/kg once every 3 weeks (Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Type, incidence and severity of ocular adverse events (AEs)Time frame: 90 days after the last dose of tisotumab vedotin
Locations
135 sites in 2 countries. Site status is shown where the registry gives one.
HonorHealth Cancer Care - Biltmore - AZCCC Imaging
Phoenix, Arizona · Recruiting
HonorHealth Cancer Care - Biltmore - HonorHealth Research Pharmacy
Phoenix, Arizona · Recruiting
HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care -Biltmore
Phoenix, Arizona · Recruiting
Sonora Quest Laboratories, LLC
Phoenix, Arizona · Recruiting
South West Medical Imaging (SMIL)
Phoenix, Arizona · Recruiting
Schwartz Laser Eye Center
Scottsdale, Arizona · Recruiting
Virginia G. Piper Cancer Pharmacy - HonorHealth Research Pharmacy
Scottsdale, Arizona · Recruiting
HonorHealth Cancer Care - Tempe - AZCCC Imaging
Tempe, Arizona · Recruiting
HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care - Tempe
Tempe, Arizona · Recruiting
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California · Recruiting
AdventHealth Hematology and Oncology Denver
Denver, Colorado · Recruiting
AdventHealth Medical Group Gynecologic Oncology at Porter
Denver, Colorado · Recruiting
Mount Sinai Comprehensive Cancer Center - Aventura
Aventura, Florida · Recruiting
Florida Cancer Specialists
Bonita Springs, Florida · Recruiting
Florida Cancer Specialists
Bradenton, Florida · Recruiting
Florida Cancer Specialists
Cape Coral, Florida · Recruiting
Broward Health Coral Springs
Coral Springs, Florida · Recruiting
Florida Cancer Specialists
Daytona Beach, Florida · Recruiting
Broward Health North
Deerfield Beach, Florida · Recruiting
Florida Cancer Specialists
Fleming Island, Florida · Recruiting
Broward Health Imperial Point
Fort Lauderdale, Florida · Recruiting
Broward Health Medical Center
Fort Lauderdale, Florida · Recruiting
Florida Cancer Specialists
Fort Myers, Florida · Recruiting
Florida Cancer Specialists
Fort Myers, Florida · Recruiting
HCA Mercy Hospital
Miami, Florida · Recruiting
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida · Recruiting
Mount Sinai Medical Center of Florida, Inc
Miami Beach, Florida · Recruiting
Florida Cancer Specialists
N. Venice, Florida · Recruiting
Florida Cancer Specialists
Naples, Florida · Recruiting
AdventHealth
Orlando, Florida · Recruiting
AdventHealth Gynecologic Oncology
Orlando, Florida · Recruiting
AdventHealth Orlando Infusion Center
Orlando, Florida · Recruiting
AdventHealth
Orlando, Florida · Recruiting
Orlando Health Ambulatory Care Center
Orlando, Florida · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
Orlando Health Orlando Regional Medical Center
Orlando, Florida · Recruiting
Orlando Health Winnie Palmer Hospital for Women & Babies
Orlando, Florida · Recruiting
Florida Cancer Specialists
Palm Beach Gardens, Florida · Recruiting
Florida Cancer Specialists
Port Charlotte, Florida · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.